EGFR and colorectal cancer: Of note, in contrast to what established for advanced colorectal cancer, in NSCLC, at present, the evidence that K-Ras mutations predict a lack of benefit from EGFR-targeting therapy is not strong enough to impose K-Ras status investigation before starting treatment [20].